KATIE CUPP: Open Payments
NPI 1710343108 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,326 in 13 payments from 6 companies in 2025. Trend: 2023 $402 · 2024 $229 · 2025 $1,326
Consulting: $630Food & beverage: $604Education: $60Travel & lodging: $33
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 5 | $968 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $149 |
| AstraZeneca Pharmaceuticals LP | 2 | $110 |
| SANOFI-AVENTIS U.S. LLC | 1 | $60 |
| PFIZER INC. | 1 | $21 |
| Novo Nordisk Inc | 1 | $18 |
Products named: DUPIXENT, OFEV, AIRSUPRA, JASCAYD, PREVNAR 20, Wegovy, TEZSPIRE.
Industry payments across NV — which companies pay providers there.
